A Phase I/II Study (JACKPOT8) of DZD4205, a Selective JAK1 Inhibitor, in Refractory or Relapsed Peripheral T- Cell Lymphoma
Won-Seog Kim(Samsung Medical Center), Jun Zhu(Shanghai Medical College of Fudan University), Yuqin Song(Peking University), Zhenfan Yang(SciencePharma (Poland)), Haiyan Yang(Zhejiang Cancer Hospital), Xubin Huang, Hyeon‐Seok Eom(National Cancer Center), Jingrun Li(Capital Medical University), Mei Wang(Jiangsu University), Kan Chen(Unknown), Jong-Seok Lee(Seoul National University Bundang Hospital), Jae‐Yong Kwak(Jeonbuk National University Hospital), Ho‐Jin Shin(Pusan National University Hospital), Xueyuan Deng, Dok-Hyun Yoon(Ulsan College), Youngil Koh(Seoul National University Hospital), Won-Sik Lee(Inje University Busan Paik Hospital)
Cited by 4
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project
|Blood|2011|431
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227
|Journal of Clinical Oncology|2022|375
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma
|New England Journal of Medicine|2022|342